November 2021 Volume 7 Issue 13

November 2021

Volume 7, Issue 13

This issue looks at classical hematology’s modern renaissance, NCI’s National Clinical Trials Network, and more.

Table of Contents

November 2021 Issue

Reflections on the Fellowship

Monday, November 1st, 2021
The American Society of Hematology (ASH) selected Jerome Seid, MD, as its 2020-2021 ASH Congressional Fellow. The Congressional Fellow program aims to connect hematologists...
You Make the Call

Reader Responses: How would you manage residual vein thrombosis in this patient with a...

Monday, November 1st, 2021
Here’s how readers responded to a You Make the Call question about management of residual vein thrombosis in a patient with a history of DVT. Disclaimer:...

APs Take the Lead in Achieving Programmatic Goals: Part Two

Monday, November 1st, 2021
Advanced practitioners (APs) are uniquely positioned within their practices to implement change, and make sure that the changes stick. ASH Clinical News Associate Editor...

Editor’s Corner: Joe’s Career Hacks

Monday, November 1st, 2021
I am by no means an expert in life coaching, but I have devoted a significant part of my career to mentoring junior faculty....

November 2021 Issue

Low-Pressure Compression Garments Helpful for Pediatric Post-Thrombotic Syndrome

Monday, November 1st, 2021
Use of graduated compression garments, a standard management for post-thrombotic syndrome (PTS) in adults, was associated with modest improvements in disease severity in children,...
The Society Pages

Remembering Elihu “Eli” Estey, Thomas Waldmann, and more

Monday, November 1st, 2021
Remembering Elihu (Eli) Estey (1946 - 2021) Renowned hematologist Elihu (Eli) Estey, MD, died suddenly on October 11, 2021, at the age of 75.After completing...

After a Pandemic-Driven Boom, Telehealth Visits Level Off

Monday, November 1st, 2021
According to recent data, telehealth visits are leveling off from their pandemic highs to below 20% of total medical appointments. Overall telehealth use for doctor’s...

FDA Grants Accelerated Approval to Zanubrutinib for Marginal Zone Lymphoma

Monday, November 1st, 2021
Zanubrutinib has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory marginal...
ASH Directions

ASH Releases Clinical Practice Guidelines on Stem Cell Transplantation in SCD, Honors Donna S....

Monday, November 1st, 2021
NEW! ASH Clinical Practice Guidelines on Stem Cell Transplantation in Sickle Cell Disease The American Society of Hematology (ASH) has published clinical practice guidelines on...
WIB_icon

Routine Screening for Germline Variants in Patients With AML

Monday, November 1st, 2021
Nearly 14% of adult patients with acute myeloid leukemia (AML) have pathogenic or likely pathogenic germline variants that make them susceptible to myeloid malignancies,...
WIB_icon

Characterizing Long-Term Outcomes of Eltrombopag in Patients With Severe Aplastic Anemia

Monday, November 1st, 2021
In an analysis of a phase II trial published in Blood, researchers found that the addition of eltrombopag to standard immunosuppression led to similar...
WIB_icon

Evaluating Pembrolizumab in Relapsed/Refractory B-Cell Lymphomas

Monday, November 1st, 2021
Pembrolizumab showed clinical benefit in patients with relapsed/refractory B-cell lymphomas following CD19-directed CAR T-cell therapy according to research findings published in Blood. Patients who responded...

Teclistamab Demonstrates Promising Efficacy, Safety in Relapsed/Refractory Multiple Myeloma

Monday, November 1st, 2021
Treatment with a subcutaneous formulation of teclistamab, a novel bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3 receptors, was well tolerated and associated...

Ixazomib-Based Regimen Induces Responses in Heavily Pretreated Waldenström Macroglobulinemia

Monday, November 1st, 2021
Treatment with proteasome inhibitor ixazomib plus subcutaneous rituximab and dexamethasone (IRD) was associated with high rates of response and manageable toxicity in patients with...

Germline Variants in DNA Repair Pathway Genes May Trigger Familial MPNs

Monday, November 1st, 2021
Germline variants in DNA repair pathway genes, such as BRCA1/2, may trigger familial myeloproliferative neoplasms (MPNs), suggesting these variants should be incorporated in diagnostic...

Modified EASIX Score Predicts CRS and ICANS Before Severe Symptoms in Patients With B-Cell...

Monday, November 1st, 2021
A modified version of the EASIX (Endothelial Activation and Stress Index) score, when calculated prior to and soon after chimeric antigen receptor (CAR) T-cell...
Sickle cell anemia

Voxelotor Granted Priority Review for Children With Sickle Cell Disease

Monday, November 1st, 2021
The U.S. Food and Drug Administration (FDA) has accepted Global Blood Therapeutics’ (GBT’s) supplemental New Drug Application (sNDA) seeking accelerated approval for voxelotor for...

Ruxolitinib Approved for Chronic Graft-Versus-Host Disease

Monday, November 1st, 2021
The FDA has approved ruxolitinib for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients 12 years and older whose disease...

New Prognostic Model Outperforms Established Predictive Models in MDS

Monday, November 1st, 2021
In a study published in the Journal of Clinical Oncology, researchers reported that a newly developed personalized prediction model comprising clinical and genomic data...

November 2021 Issue

Pulling Back the Curtain: Carlo Brugnara, MD

Monday, November 1st, 2021
In this edition, Carlo Brugnara, MD, talks about working in his parents’ bakery and pasta factory during childhood and his first role in academic...

Classical Hematology: A Specialty in Decline?

Monday, November 1st, 2021
As workforce shortages persist, this ancient art is undergoing a modern renaissance. Two factors influenced Alfred Ian Lee, MD, PhD, to specialize in classical hematology....

November 2021 Issue

The Evolution of the National Cancer Institute’s National Clinical Trials Network

Monday, November 1st, 2021
Just over 10 years ago, the National Cancer Institute (NCI) shook up the hematology/oncology clinical trial landscape by reorganizing its various cooperative research groups...
You Make the Call

You Make the Call: How would you manage residual vein thrombosis in this patient...

Monday, November 1st, 2021
This month, Allyson Pishko, MD, MSCE, discusses management of residual vein thrombosis in a patient with a history of DVT. And don't forget to check...